References


7. Teva Branded Pharmaceutical Products, R&D Inc. A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma. Available from: https://clinicaltrials.gov/ct2/show/NCT01270464. NLM identifier: NCT01270464.

8. Teva Branded Pharmaceutical Products, R&D Inc. A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma. NLM identifier: NCT01287039.


